logo-loader
viewRegen Biopharma, Inc.

Regen BioPharma, Inc. announced drug discovery agreement with Eli Lilly and Company

Regen will receive compounds from Lilly for drug discovery purposes

deal_57752e848510c.jpg
As part of the deal, Regen will examine 21,000 Lilly-owned compounds

Shares in Regen BioPharma, Inc (OTCQB: RGBP, OTCQB: RGBPP) shot higher as the firm announced it had entered into a definitive agreement with Eli Lilly and Co (NYSE:LLY).

Regen will receive compounds from Lilly for drug discovery purposes, as well as share structural information on compounds.

It also paves the way for the two companies to negotiate future compound purchase agreements, license agreements, and research collaboration agreements.

“They understand the value of partnering in a confidential manner with smaller entities that may have intellectual property that aligns with their product goals,” Harry Lander, president and chief scientific officer of Regen said.

As part of the deal, Regen will examine 21,000 Lilly-owned compounds in its NR2F6 high-throughput screening program.

NR2F6 is a molecular switch known as an "orphan nuclear receptor," which controls genes associated with the immune response as well as genes associated with the ability of cancer stem cells to propagate.

Quick facts: Regen Biopharma, Inc.

Price: 0.0001 USD

PINK:RGBP
Market: PINK
Market Cap: $57.15 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Atlas Engineered Products Co-founder talks company's rich...

Atlas Engineered Products (CVE: AEP) Co-founder Hadi Abasi dropped into the Vancouver Studio of Proactive to discuss the growing company and their humble beginnings.  Abassi also talked about a major hire for the company that he feels has set them up for great success in the future.

45 minutes ago

2 min read